These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3141267)

  • 1. [Comparative antibacterial activity of fleroxacin: selection frequencies and outer membrane proteins of resistant mutants].
    Cullmann W; Dechène M; Stieglitz M
    Immun Infekt; 1988 Aug; 16(4):152-8. PubMed ID: 3141267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the outer membrane for quinolone resistance in enterobacteria.
    Dechène M; Leying H; Cullmann W
    Chemotherapy; 1990; 36(1):13-23. PubMed ID: 2106416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents.
    Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC
    Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.
    Pace J; Bertasso A; Georgopapadakou NH
    Antimicrob Agents Chemother; 1991 May; 35(5):910-5. PubMed ID: 1649574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fleroxacin resistance in Escherichia coli.
    Chapman JS; Bertasso A; Georgopapadakou NH
    Antimicrob Agents Chemother; 1989 Feb; 33(2):239-41. PubMed ID: 2541657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A; Benonisen E; Salveson A; Zahm F
    Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the combination trimethoprim plus sulfamethoxazole compared with that of other chemotherapeutic agents.
    Focht J; Klietmann W; Nösner K
    Arzneimittelforschung; 1988 Aug; 38(8):1085-8. PubMed ID: 3264166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
    Sobottka I; Neumann S; Laufs R
    Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of an efflux pump in Serratia marcescens.
    Berlanga M; Vázquez JL; Hernandez-Borrell J; Montero MT; Viñas M
    Microb Drug Resist; 2000; 6(2):111-7. PubMed ID: 10990265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens.
    Watanabe M; Kotera Y; Yosue K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1990 Jan; 34(1):173-5. PubMed ID: 2183709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro antibacterial activity of piperacillin/quinolone combinations].
    Soussy CJ; Leclercq R; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):357-60. PubMed ID: 3136421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
    Verschraegen G; Claeys G; Van den Abeele AM
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):63-6. PubMed ID: 3132381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the ability of newer beta-lactam antibiotics to select resistant mutants from Serratia marcescens after mutagenesis with nitrosoguanidine.
    Vuye A; Baert E; Kersters K; Declerck D; Vanhaecke E; Pijck J
    Arzneimittelforschung; 1989 Apr; 39(4):424-7. PubMed ID: 2502123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibility of gram negative bacteria to TMP-SMX and ofloxacin].
    Unal S; Aydin M; Akin A
    Mikrobiyol Bul; 1988; 22(4):316-21. PubMed ID: 3266971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smaqnr, a new chromosome-encoded quinolone resistance determinant in Serratia marcescens.
    Velasco C; Rodríguez-Martínez JM; Briales A; Díaz de Alba P; Calvo J; Pascual A
    J Antimicrob Chemother; 2010 Feb; 65(2):239-42. PubMed ID: 19942618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid-mediated formaldehyde resistance in Serratia marcescens and Escherichia coli: alterations in the cell surface.
    Kaulfers PM; Karch H; Laufs R
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Aug; 266(1-2):239-48. PubMed ID: 3321766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.